Financings

Longbio to raise HK$1.4B in Hong Kong IPO for immunology work

Tue, 02 Jun 2026 12:00:00 -0400

Chinese biotech Longbio Pharma Co. Ltd. announced its IPO on the Hong Kong Stock Exchange to raise HK$1.362 billion (US$174 million) to progress its lead candidate, LP-003, a next-generation anti-IgE antibody.

Financings for June 2, 2026

Tue, 02 Jun 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Briacell, Oak Hill, Yoltech.

IMU’s $53M series A to advance high-definition immune profiling tech

Tue, 02 Jun 2026 12:00:00 -0400

IMU Bioscience Ltd. has closed its series A at £40 million (US$53.9 million), adding £28.5 million to the initial close in January 2024, and bringing the total raised since the company’s formation in 2021 to £45 million. Since that first close, IMU has built what is claimed as the world’s largest high-definition immune system dataset, with almost 25,000 profiles of healthy volunteers and disease-specific patient cohorts.

MJFF grants supports Lysoway’s TMEM175 agonist program

Tue, 02 Jun 2026 09:00:00 -0400

Lysoway Therapeutics Inc. has been awarded an additional research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support development of its TMEM175 agonist program for Parkinson’s disease.

Series A financing at Waypoint Bio supports CAR T programs

Tue, 02 Jun 2026 09:00:00 -0400

Waypoint Bio has closed a $20 million series A financing round to support its work developing next-generation in vivo CAR T therapeutics for solid tumors using a platform that integrates AI, computer vision and spatial pooled screening.

Financings for June 2, 2026

Tue, 02 Jun 2026 08:00:00 -0400

Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Hanchorbio, Longbio.

Financings for June 1, 2026

Mon, 01 Jun 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Longbio, OSE, Outlook, Tempest.

Laverock Therapeutics awarded innovation grants

Mon, 01 Jun 2026 09:00:00 -0400

Laverock Therapeutics Ltd. has been awarded two new grants totaling in excess of £2.2 million (US$3 million) to support the next generation of its gene-control platform development, and expansion into additional nononcology therapeutics areas.

Financings for May 29, 2026

Fri, 29 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Countable Labs, Maculaser, Medicenna, Medicus, Polaryx, Psilera, Secretome, Veraxa.

Longbio to raise HK$1.4B in Hong Kong IPO for immunology work

Thu, 28 May 2026 12:00:00 -0400

Financings for May 28, 2026

Thu, 28 May 2026 10:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Assembly, Bleednfire, Clearnote Health, Kardigan, Protuoso, Q32, Reprogram.

Protuoso Biosciences building multifunctional protein engineering platform

Thu, 28 May 2026 09:00:00 -0400

Protuoso Biosciences has announced the close of an oversubscribed $9.5 million seed financing round, the proceeds of which will be used to advance its multifunctional protein engineering platform and broad pipeline across cardiometabolic, oncology and autoimmune diseases.

Reprogram Biosciences secures financing for solid tumor mRNA work

Thu, 28 May 2026 09:00:00 -0400

Reprogram Biosciences Inc., a preclinical oncology biotechnology company developing mRNA-based therapeutics to treat solid tumors, has announced the close of its seed financing, bringing the total capital raised to $6 million since the company’s founding in 2025.

Financings for May 27, 2026

Wed, 27 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Biostem, Cartesian, Editas, Hanchorbio, Kane, Mindmaze, Nanobiotix, Rani.

Financings for May 26, 2026

Tue, 26 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Assembly, HCW, Jupiter, Nanobiotix, Nervgen, Synakis.

Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline

Tue, 26 May 2026 11:00:00 -0400

Antimicrobial-focused Tennor Therapeutics Ltd. will debut in Hong Kong May 22, having priced a HK$626.84 million (US$80 million) IPO. The Suzhou, China-based biotech is waiting on China’s National Medical Products Administration approval of lead asset rifasutenizol (TNP-2198), which has potential to become the first targeted combination regimen to treat H. pylori infection.

Financings for May 26, 2026

Tue, 26 May 2026 08:00:00 -0400

Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Accro, Forlong, Full-Life Technologies.

Financings for May 22, 2026

Fri, 22 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Aim Immunotech, Akari, Immix, Jupiter, Relay, Theralase.

Financings for May 21, 2026

Thu, 21 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Annovis, Avricore, Co-Diagnostics, Neurosoft, Oorja Bio, Parabilis, Proencia, Regeneron, Resverlogix.

Tennor’s $80M Hong Kong IPO to fund antibacterial drug pipeline

Thu, 21 May 2026 12:00:00 -0400

Financings for May 20, 2026

Wed, 20 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Accro, Brainstorm, Forlong, Full-Life, Lauxera Capital, Nanoviricides, Sunshine, Tarsier, Violet, Vortex.

Re-Aim Therapeutics launches with focus on autoimmune diseases

Wed, 20 May 2026 09:00:00 -0400

Re-Aim Therapeutics Ltd. has launched with £7 million (US$9.4 million) in seed investment backing and a focus on developing functional cures for T-cell-mediated autoimmune diseases.

Degron closes $40M series A to advance molecular glue degraders

Tue, 19 May 2026 12:00:00 -0400

Degron Therapeutics Inc. closed a $40 million series A extension round that will see the company advance its molecular glue degraders targeting previously undruggable or insufficiently drugged proteins.

Financings for May 19, 2026

Tue, 19 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: MS Pharma, Orphai, Quince, Rein, Silexion.

Create Medicines secures $122M for in vivo CARs

Tue, 19 May 2026 12:00:00 -0400

Create Medicines Inc. closed a $122 million series B financing round to support its pipeline of therapies that use mRNAs delivered via liquid nanoparticles to express chimeric antigen receptors (CARs) in T cells, NK cells and myeloid cells inside the body of patients. The Cambridge, Mass.-based company estimates the capital will last through 2028, providing the opportunity for multiple clinical readouts of its various products.

Financings for May 19, 2026

Tue, 19 May 2026 08:00:00 -0400

Biopharma and med-tech companies in Asia-Pacific raising money in public or private financings: Degron, Ninamed.

Financings for May 18, 2026

Mon, 18 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Imperative Care.

Degron closes $40M series A to advance molecular glue degraders

Mon, 18 May 2026 12:00:00 -0400

Financings for May 15, 2026

Fri, 15 May 2026 12:00:00 -0400

Biopharma and med-tech companies raising money in public or private financings, including: Armata, Bluewind Medical, Butterfly, Capehaven, Create Medicines, Degron, EBT, Mezzion, Ninamed, Urologic Health, Uromems, Xortx.

Sonomind raises €20M for ultrasound neuromodulation technology

Fri, 15 May 2026 12:00:00 -0400

Sonomind SAS raised €20 million (US$23 million) in a series A funding round for its ultrasound-based neuromodulation technology for depression. The funds will be used for clinical trials of the non-invasive device, which uses a custom-made acoustic lens to precisely target deep regions within the brain to bring relief to patients suffering from treatment-resistant depression.